ArticleFrontiers in surgery2026
Research on the application of cerebral blood flow reconstruction technology in the surgical treatment of moyamoya disease.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Moyamoya disease (MMD) is characterized by stenosis and occlusion of the cerebral arteries, leading to chronic progressive narrowing at the termini of the bilateral internal carotid arteries (ICA). It represents one of the primary etiologies for both ischemic and hemorrhagic strokes ( 1, 2).Currently, the primary treatment strategy for moyamoya disease (MMD) remains blood flow reconstruction surgery utilizing a bypass from the superficial temporal artery (STA) to the middle cerebral artery (MCA). This approach encompasses direct blood flow reconstruction, indirect blood flow reconstruction, and combined methods of blood flow reconstruction ( 3). However, there remains a paucity of high-quality results from clinical randomized controlled trials. This study aims to summarize the key points, selection criteria, and therapeutic effects of various surgical methods, thereby providing a foundation and accumulating experience for moyamoya disease (MMD) surgery. Method: A retrospective analysis was conducted on the clinical data of adult patients with moyamoya disease who underwent superficial temporal artery-middle cerebral artery + brain-muscle fusion (EMS) combined with blood flow reconstruction (EMS group) and superficial temporal artery-middle cerebral artery + pedicled temporoparietal fascia flap (TPFF) combined with blood flow reconstruction (TPFF group). Summarize and analyze the differences in technical characteristics, clinical efficacy, complications and prognosis between the two surgical methods; A retrospective analysis was conducted on the clinical data of adult patients with moyamoya disease who underwent the double-vessel ST-MCA + EMS group (double-vessel group) and the single-vessel ST-MCA + EMS group (single-vessel group). The technical characteristics, clinical efficacy, complications and prognosis differences of the two surgical methods were summarized and analyzed. Result: The incidence of postoperative epilepsy in the TPFF group was significantly lower than that in the EMS group ( Conclusion: This study further confirmed that STA-MCA + TPFF is a safe and effective combined blood flow reconstruction surgical method for the treatment of adult MMD, and it has the advantages of less trauma, simple operation, and avoiding adverse reactions caused by temporal muscle application, and can be used for clinical promotion and application. Both double and single STA-MCA + EMS can effectively improve cerebral perfusion in adult MMD patients. Individualized and reasonable choices should be made based on specific conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.